Group One Trading
BCRX icon

Group One Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

Group One Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$727K Sell
72,749
-63,533
-47% -$575K ﹤0.01% 3165
2026
Q1 		$1.3M Buy
136,282
+75,758
+125% +$588K ﹤0.01% 2468
2025
Q4 		$472K Buy
60,524
+20,997
+53% +$152K ﹤0.01% 3580
2025
Q3 		$300K Buy
+39,527
New +$329K ﹤0.01% 4226
2024
Q2 		– Sell
-46,044
Closed -$254K – 6715
2024
Q1 		$234K Buy
46,044
+14,616
+47% +$82.2K ﹤0.01% 3423
2023
Q4 		$188K Buy
31,428
+19,537
+164% +$113K ﹤0.01% 3920
2023
Q3 		$84.2K Buy
+11,891
New +$85.4K ﹤0.01% 4613
2023
Q2 		– Sell
-100,976
Closed -$810K – 7641
2023
Q1 		$842K Sell
100,976
-61,572
-38% -$593K ﹤0.01% 2282
2022
Q4 		$1.87M Buy
162,548
+91,174
+128% +$1.14M ﹤0.01% 1885
2022
Q3 		$899K Sell
71,374
-75,072
-51% -$966K ﹤0.01% 2681
2022
Q2 		$1.55M Buy
+146,446
New +$1.51M ﹤0.01% 2298
2022
Q1 		– Sell
-138,644
Closed -$2.22M – 8018
2021
Q4 		$1.92M Buy
138,644
+21,459
+18% +$284K ﹤0.01% 2643
2021
Q3 		$1.68M Buy
+117,185
New +$1.85M ﹤0.01% 2839
2021
Q2 		– Sell
-123,699
Closed -$1.68M – 8133
2021
Q1 		$1.26M Sell
123,699
-92,326
-43% -$952K ﹤0.01% 2966
2020
Q4 		$1.61M Buy
216,025
+79,048
+58% +$408K ﹤0.01% 2227
2020
Q3 		$471K Buy
136,977
+54,452
+66% +$233K ﹤0.01% 2902
2020
Q2 		$393K Buy
+82,525
New +$330K ﹤0.01% 2829
2020
Q1 		– Sell
-5,558
Closed -$15.3K – 5255
2019
Q4 		$19K Buy
5,558
+2,473
+80% +$6.22K ﹤0.01% 4378
2019
Q3 		$9K Sell
3,085
-101,205
-97% -$315K ﹤0.01% 4619
2019
Q2 		$395K Buy
104,290
+101,470
+3,598% +$611K ﹤0.01% 2348
2019
Q1 		$23K Buy
+2,820
New +$24.1K ﹤0.01% 3954
2018
Q4 		– Sell
-3,879
Closed -$30.2K – 4869
2018
Q3 		$30K Sell
3,879
-3,404
-47% -$22.9K ﹤0.01% 4225
2018
Q2 		$42K Buy
7,283
+4,295
+144% +$23.6K ﹤0.01% 4041
2018
Q1 		$14K Buy
2,988
+1,594
+114% +$8.19K ﹤0.01% 4203
2017
Q4 		$7K Sell
1,394
-45,973
-97% -$223K ﹤0.01% 4470
2017
Q3 		$248K Buy
+47,367
New +$243K ﹤0.01% 2611
2017
Q2 		– Sell
-95,908
Closed -$584K – 4740
2017
Q1 		$806K Buy
95,908
+14,732
+18% +$102K 0.01% 1491
2016
Q4 		$514K Buy
81,176
+77,460
+2,084% +$403K 0.01% 1756
2016
Q3 		$16K Sell
3,716
-9,181
-71% -$36.7K ﹤0.01% 3873
2016
Q2 		$37K Buy
12,897
+6,719
+109% +$20.9K ﹤0.01% 3477
2016
Q1 		$17K Buy
+6,178
New +$27.4K ﹤0.01% 3814
2015
Q4 		– Sell
-2,770
Closed -$27.5K – 4735
2015
Q3 		$32K Buy
+2,770
New +$37K ﹤0.01% 3799
2015
Q2 		– Sell
-9,735
Closed -$111K – 4843
2015
Q1 		$88K Buy
+9,735
New +$101K ﹤0.01% 2977
2014
Q4 		– Sell
-15,064
Closed -$166K – 4886
2014
Q3 		$147K Buy
+15,064
New +$185K ﹤0.01% 2644
2014
Q2 		– Sell
-6,599
Closed -$64.2K – 5163
2014
Q1 		$70K Sell
6,599
-64,526
-91% -$688K ﹤0.01% 3373
2013
Q4 		$541K Buy
71,125
+36,320
+104% +$230K 0.01% 1607
2013
Q3 		$253K Buy
34,805
+19,686
+130% +$99.9K ﹤0.01% 2174
2013
Q2 		$23K Buy
+15,119
New +$26.1K ﹤0.01% 3985

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Group One Trading's BCRX Position: Q2 2026 in Review

Group One Trading reduced its BioCryst Pharmaceuticals (BCRX) stake by 47% in Q2 2026, selling an estimated $575K and leaving 72,749 shares worth $727K. The position accounts for ﹤0.01% of the portfolio, ranked #3165.

Group One Trading first reported a position in BCRX in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.92M in Q4 2021. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Group One Trading held 72,749 shares of BioCryst Pharmaceuticals worth $727K as of Q2 2026.
  • Group One Trading sold 63,533 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $575K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #3165 holding.
  • Group One Trading first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 38 quarters since.
  • Group One Trading's BioCryst Pharmaceuticals position peaked at $1.92M in Q4 2021.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.